Statera Biopharma, Inc.

Equities

STAB

US8575611046

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
0.0006 ^USD	0.00%		0.00%	0.00%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Nasdaq Resumes Trading in Statera Biopharma, Inc.

August 26, 2022 at 07:50 am EDT

NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market^® (Nasdaq: NDAQ) announced that trading resumed in Statera Biopharma, Inc. (Nasdaq: STAB) today, August 26, 2022 at 7:10 a.m. Eastern Time. Trading in the company’s stock was halted on August 25, 2022 at 11:01:52 a.m. Eastern Time.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SMon the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

NDAQO

Nasdaq Media Contact:
Sophia Weiss
Sophia.Weiss@nasdaq.com

Source: Nasdaq, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Latest news about Statera Biopharma, Inc.

Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	23-03-14	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	23-01-17	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index	23-01-11	CI
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation	22-11-06	CI
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding	22-10-31	CI
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-28	CI
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-10-21	CI
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data	22-10-21	MT
Top Premarket Gainers	22-10-21	MT
Top Premarket Decliners	22-10-18	MT
Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.	22-10-16	CI
Top Premarket Decliners	22-10-07	MT
Wall Street Set to Open Lower as Jobless Claims Rise	22-10-06	MT
US Futures Lower as Prices Fuel Investors' Inflation Concerns	22-10-06	MT
Top Premarket Gainers	22-10-06	MT
Statera Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-10-06	CI
Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	22-10-05	CI
Certain Warrants of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Options of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Restricted stock units of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Common Stock of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Statera Biopharma, Inc. Announces Board Changes	22-09-09	CI
Statera Biopharma Receives Additional Non-Compliance Notice From Nasdaq	22-08-26	MT
Statera Biopharma Stock Trading Halted Pending Nasdaq's Information Request	22-08-25	MT

Chart Statera Biopharma, Inc.

Duration

Period

More charts

Company Profile

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
STATERA BIOPHARMA, INC.	0.00%	43.55K
IQVIA HOLDINGS INC.	-1.96%	41.36B
LONZA GROUP AG	+44.25%	41.3B
MODERNA, INC.	+2.67%	39.61B
CELLTRION, INC.	-12.11%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.38%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.19%	18.38B
MEDPACE HOLDINGS, INC.	+23.35%	11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.05%	11.82B
UNITED THERAPEUTICS CORPORATION	+7.94%	11.07B

Other Biotechnology & Medical Research